NCT03900572View on ClinicalTrials.gov

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 9, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
HPV Infections
Interventions
BIOLOGICAL

HPV Vaccine

Intramuscular injection, 3 doses

DRUG

Placebo

Intramuscular injection, 3 doses

Trial Locations (1)

610041

Sichuan Provincial Center for Disease Prevention and Control, Chengdu

All Listed Sponsors
lead

Shanghai Zerun Biotechnology Co.,Ltd

INDUSTRY

NCT03900572 - A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine | Biotech Hunter | Biotech Hunter